Physician profile
Lisa Li
NPI 1851326151
$5,412.82
in general payments reported to CMS, 2019-2025
28 companies · $951 in 2025
The $951 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $765 · 2021: $826 · 2022: $545 · 2023: $490 · 2024: $876 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,302 · Education: $14.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,302.47 |
| Education | $14.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,237.18 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Novo Nordisk INC | $1,017.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $446.95 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $372.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $370.08 | 2019-2024 | |
| Pfizer INC. | $351.26 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $251.29 | 2021-2025 | |
| Astellas Pharma US INC | $199.32 | 2019-2022 | |
| Exact Sciences Corporation | $166.35 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $157.00 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.74 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $107.12 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $96.81 | 2019-2022 | |
| Boston Scientific Corporation | $78.79 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $77.58 | 2023-2025 | Rexulti, Nuedexta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $63.24 | 2020-2023 | Trelegy Ellipta |
| Cumberland Pharmaceuticals, INC. | $59.93 | 2022-2024 | Kristalose |
| Abbott Laboratories | $48.40 | 2022-2025 | Freestyle Libre 3 |
| Paratek Pharmaceuticals, INC. | $24.68 | 2025 | Nuzyra, Xhance |
| Allergan, INC. | $24.58 | 2020 | |
| Sumitomo Pharma America, INC. | $17.67 | 2025 | Gemtesa |
| Renalytix Ai, INC. | $17.51 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Avanir Pharmaceuticals, INC. | $14.76 | 2019 | |
| Currax Pharmaceuticals LLC | $14.03 | 2025 | Contrave |
| Dexcom, INC. | $12.97 | 2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $12.00 | 2021 | |
| Althera Pharmaceuticals LLC | $11.81 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.